BioVersys announced a collaboration with GlaxoSmithKline to develop a preclinical candidate against tuberculosis, funded by the Wellcome Trust. The collaboration will utilize BioVersys’ award-winning innovative TRIC technology that enables the discovery of Transcriptional Regulator Inhibitory Compounds. The project, built upon a very long history of TB research in Lille, will advance molecules that reactivate the efficacy of established TB therapies.
Source: BioVersys